All In Biotech

Drug Trial Radar · NCT05583838

A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts

Comparing the Efficacy and Safety of Optimized rhTPO Treatment Versus Eltrombopag Treatment in Previously Treated Primary Immune Thrombocytopenia Patients: A Multicenter Randomized Open-label Trial

Last checked: Nov 20, 2026Latest source record: Apr 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 157 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

157

Actual

Start

Nov 22, 2022

Primary completion

Feb 28, 2024

Study completion Jul 16, 2024

Sponsor

Lead sponsor
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The Second Hospital of Hebei Medical University; Xijing Hospital; The Affiliated Hospital of Inner Mongolia Medical University; The Second Affiliated Hospital of Kunming Medical University; Second Affiliated Hospital of Guangzhou Medical University; Shaanxi Provincial People's Hospital; Henan Cancer Hospital; North China University of Science and Technology; The Second Affiliated Hospital of Dalian Medical University; Second Hospital of Shanxi Medical University; The Second Affiliated Hospital of Harbin Medical University; Shenyang Sunshine Pharmaceutical Co., LTD.; First Affiliated Hospital of Xinjiang Medical University; People's Hospital of Xinjiang Uygur Autonomous Region; Kashgar 1st People's Hospital; Xi'an Central Hospital; Beijing Public Health Foundation; Yuyao People's Hospital
First posted
Oct 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TE-ITP study: Compare the efficacy and safety of optimized rhTPO treatment versus Eltrombopag treatment in previously treated primary immune thrombocytopenia patients.

Conditions

  • Previously Treated Primary Immune Thrombocytopenia

Interventions

  • rhTPODrug

    initial therapy: rhTPO s.c, 300 or 600U/kg daily based on baseline platelet count; maintenance therapy: rhTPO s.c, 300 \~ 600U/kg every other day depends on platelet count.

  • EltrombopagDrug

    initial therapy: Eltrombopag oral, 25 or 50mg daily based on baseline platelet count; maintenance therapy: Eltrombopag oral, 25 \~ 75mg daily or every other day depends on platelet count.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Median time to achieve platelet count ≥50x10^9/L during 6 weeks observationTime frame: in 6 weeks treatment

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China

  • the Second Hospital of HeBei Medical University

    Shijiazhuang, Hebei, China

  • North China University of Science and Technology Affiliated Hospital

    Tangshan, Heibei, China

  • The Second Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital

    Zhengzhou, Henan, China

  • The Affiliated Hospital of Inner Mongolia Medical University

    Hohhot, Inner Mongolia, China

  • The Second Hospital of Dalian Medical University

    Dalian, Liaoning, China

  • Xi'an Central Hospital

    Xi'an, Shaanxi, China

  • Xijing Hospital of the Fourth Military Medical University

    Xi'an, Shaanxi, China

  • Shaanxi Provincial People's Hospital

    Xi'an, Shaanxi, China

  • Chinese Academy of Medical Science and Blood Disease Hospital,CAMS & PUMC

    Tianjin, Tianjin Municipality, China

  • The Second Hospital of Tianjin Medical University

    Tianjin, Tianjin Municipality, China

  • Kashgar District 1st People's Hospital

    Kashgar, Xinjiang, China

  • People's Hospital of Xinjiang Uygur Autonomous Region

    Ürümqi, Xinjiang, China

  • The first affiliated Hospital of Xinjiang Medical University

    Ürümqi, Xinjiang, China

  • The Second Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan, China

  • Yuyao People's Hospital of Zhejiang Province

    Yuyao, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.